New study looks at efficacy of Neoadjuvant Intraperitoneal Chemotherapy in Unresectable PMP Patients

Andreas Brandl

EuroPMP member Andreas Brandl has recently, in collaboration with Yutaka Yonemura, published a new paper looking into the efficacy of neoadjuvant intraperitoneal chemotherapy in patients who were not candidates for cytoreductive surgery at the time of diagnosis. The study showed low morbidity and mortality when neoadjuvant intraperitoneal chemotherapy was given to patients, and appears to show a higher rate of complete cytoreduction compared to the traditional treatment afforded these patients. The study is still ongoing and will report on the long-term survival characteristics of these and more patients in the future.

The new paper may be read here.